Securities Lawsuit Filed Against Centene Corporation and Senior Executives

Strategic Insights -

A lawsuit has been filed against Centene Corporation, a leading healthcare company, and its senior executives for potential violations of federal securities laws. The lawsuit was filed by a securities law firm on behalf of investors who purchased Centene securities. The complaint alleges that the company made false statements about its financial performance and enrollment growth, leading to a decline in stock price. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Lunstrum v. Centene Corporation, et al.

Key Takeaways:

  • Centene Corporation, a healthcare company, was sued for potential securities law violations by a leading securities law firm.
  • The lawsuit was filed on behalf of investors who purchased Centene securities and alleges that the company made false statements about its financial performance and enrollment growth.
  • The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
  • The case is pending in the U.S. District Court for the Southern District of New York and is captioned Lunstrum v. Centene Corporation, et al.
  • The lawsuit follows a series of statements made by Centene about its financial guidance, which caused the company's stock price to decline when the truth was revealed.
  • Centene's stock price fell $22.87 per share, or more than 40%, after the company withdrew its guidance due to negative enrollment growth and increased morbidity rates.
  • Investors who purchased Centene securities may have legal options and are encouraged to submit their information to the firm.
  • The firm will seek court approval for any potential fees and expenses.

Statistics:

  • Centene's stock price fell $22.87 per share, or more than 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025.
  • The case is captioned Lunstrum v. Centene Corporation, et al. , No. 25-cv-05659.
  • The complaint was filed by a leading securities law firm, Bleichmar Fonti & Auld LLP.
  • The firm recovered over $900 million in value from Tesla, Inc.'s Board of Directors and $420 million from Teva Pharmaceutical Ind. Ltd.

Sources:

  • GLOBE NEWSWIRE: August 17, 2025 (Cnt)
  • Bleichmar Fonti & Auld LLP: (Cnt)